Are you experiencing weight gain after stopping GLP-1
According to the TRICARE website, coverage depends on whether your reason for taking Wegovy meets certain criteria and if you have a prescription from a licensed medical provider
August 2025 : The US FDA approved Wegovy (semaglutide 2.4 mg) for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced-calorie diet and increased physical activity
Weve already discussed the use of GLP-1s combined with hormone replacement therapy in midlife women
Athletes and physically active individuals may potentially benefit from the wound healing and anti-inflammatory properties of these peptides in treating common sports-related injuries including muscle strains, tendon injuries, and ligament sprains
Then according to the patients situation, providers prescribe different medications as well as dietary changes and supplements
